2m 2m 2m 2m 2m 2m 2m
ALX ONCOLOGY (ALXO)
NASDAQ
$1.68-$0.10 (-5.90%)
Price as of Jun 03, 2026 5:51 PM EDT- $255.7MMarket Cap
- 220.89%1-Year Change
- BiotechnologyIndustry
ALX ONCOLOGY (ALXO)
$1.68-$0.10 (-5.90%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 -100.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -77.0M -33.84% | -116.4M -17.93% | -141.8M +44.10% | -98.4M +63.54% | |
Depreciation and Amortization Expense | 706,000 -19.04% | 872,000 +4.31% | 836,000 +144.44% | 342,000 +570.59% | |
Total Operating Expenses | 104.0M -26.99% | 142.5M -16.33% | 170.3M +33.62% | 127.4M +52.52% | |
Operating Profit | -104.0M -26.99% | -142.5M -16.33% | -170.3M +33.62% | -127.4M +52.52% | |
Interest Income | 4.0M -57.68% | 9.4M -12.05% | 10.6M +10,549.00% | 100,000 N/A | |
Interest Expense | -1.6M -7.35% | -1.7M +10.48% | -1.6M +682.50% | -200,000 +1,438.46% | |
Interest Income and Expense and Net | 2.4M -69.07% | 7.6M -15.93% | 9.1M +9,184.00% | -100,000 +669.23% | |
Total Nonoperating Income and Expense | -36,000 +80.00% | -20,000 -105.14% | 389,000 +249.62% | -260,000 -409.52% | |
Income before Taxes | -101.7M -24.59% | -134.8M -16.14% | -160.8M +30.29% | -123.4M +47.83% | |
Income Taxes | 0 -100.00% | 64,000 0.00% | 64,000 0.00% | 64,000 +404.76% | |
Extraordinary Items | 3.2M N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | -101.7M -24.59% | -134.8M -16.14% | -160.8M +30.23% | -123.5M +47.95% | |
Net Income from Continuing Operations Applicable to Common | -101.7M -24.59% | -134.8M -16.14% | -160.8M +30.23% | -123.5M +47.95% | |
Basic EPS and Net Income | -1.90 -26.36% | -2.58 -31.02% | -3.74 +23.43% | -3.03 +46.38% | |
Diluted EPS and Net Income | -1.90 -26.36% | -2.58 -31.02% | -3.74 +23.43% | -3.03 +46.38% | |
Basic Weighted Average Shares | 53.7M +2.84% | 52.2M +21.37% | 43.0M +5.62% | 40.7M +0.97% | |
Diluted Weighted Average Shares | 53.7M +2.84% | 52.2M +21.37% | 43.0M +5.62% | 40.7M +0.97% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 16.4M -6.80% | 17.6M -21.60% | 22.4M -54.11% | 48.8M -86.58% | |
Short-Term Investments | 28.4M -74.21% | 110.2M -31.27% | 160.3M -26.25% | 217.4M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 44.8M -64.94% | 127.8M -30.09% | 182.7M -31.36% | 266.2M -26.80% | |
Total Current Assets | 50.7M -62.24% | 134.4M -28.79% | 188.7M -30.38% | 271.0M -26.17% | |
Accumulated Depreciation | 2.0M -4.72% | 2.1M +67.91% | 1.2M +206.95% | 403,000 +539.68% | |
Property and Plant and Equipment and Net | 1.2M -58.69% | 2.9M -19.06% | 3.6M -7.71% | 3.9M +333.56% | |
Total Long-Term Assets | 3.6M -48.17% | 7.0M -53.04% | 14.9M -0.25% | 14.9M +21.72% | |
Total Assets | 59.0M -60.04% | 147.8M -39.08% | 242.6M -20.86% | 306.5M -19.38% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.2M +1,099.31% | 435,000 N/A | 0 -100.00% | 1.6M N/A | |
Total Current Liabilities | 24.6M +32.72% | 18.5M -48.61% | 36.0M +27.10% | 28.3M +85.19% | |
Total Long-Term Debt | 4.5M -52.14% | 9.5M -1.76% | 9.6M +2.66% | 9.4M N/A | |
Total Long-Term Liabilities | 4.0M -35.68% | 6.2M -14.07% | 7.2M +35.59% | 5.3M +188.80% | |
Total Liabilities | 33.1M -3.20% | 34.2M -35.36% | 52.8M +22.81% | 43.0M +151.11% | |
Retained Earnings | -722.8M +16.37% | -621.1M +27.73% | -486.3M +49.41% | -325.5M +61.13% | |
Total Stockholders Equity | 26.0M -77.13% | 113.6M -40.11% | 189.7M -27.99% | 263.5M -27.43% | |
Total Shares Outstanding | 54.4M +2.52% | 53.1M +6.21% | 50.0M +22.25% | 40.9M +0.68% | |
Cash Flow | |||||
Cash from Operating Activities | -84.1M -30.98% | -121.9M -6.48% | -130.4M +46.11% | -89.2M +31.02% | |
Capital Expenditures | 212,000 -52.57% | 447,000 -64.91% | 1.3M -10.72% | 1.4M +114.26% | |
Cash from Investing Activities | 82.6M -4.25% | 86.3M +93.15% | 44.7M +118.97% | -235.4M +4,681.96% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 362,000 -98.83% | 30.8M -48.02% | 59.3M +501.33% | 9.9M +298.87% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -98.34% +42.33% | -69.10% +17.96% | -58.58% +62.87% | -35.97% +75.86% | |
Return on Equity | -145.70% +63.86% | -88.91% +25.29% | -70.97% +80.04% | -39.42% +87.24% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | -100.00% N/A | |
Current Ratio | 2.07 -71.55% | 7.26 +38.58% | 5.24 -45.22% | 9.57 -60.13% | |
Cash Ratio | 0.67 -29.78% | 0.95 +52.57% | 0.62 -63.89% | 1.72 -92.75% | |
Debt-to-Equity Ratio | 0.38 +330.28% | 0.09 +71.65% | 0.05 +21.24% | 0.04 N/A | |
Debt-to-Assets Ratio | 0.17 +146.42% | 0.07 +68.77% | 0.04 +10.28% | 0.04 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow